If you’re a federal employee and have questions about continuing coverage, please speak to your Patient Benefits Specialist and visit our insurance page here: virginiacancerspecialists.com/insurance/.
A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. After binding to CD22, epratuzumab’s predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC). Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
